TLR4 and early-onset autosomal dominant Alzheimer disease: Systemic administration of a weak TLR4 agonist monophosphoryl lipid A (MPLA) led to a substantial reduction in amyloid β load in the brain and to a significant improvement in Alzheimer’s-disease-related pathology in mice [99].